Gossamer Bio's (GOSS) Seralitinib Data Likely Comes Out by Feb - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Gossamer Bio Inc. (NASDAQ: GOSS).The analyst commented, "Management is still ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


